The present and future of gene profiling in breast cancer.

E. Espinosa, A. Gámez-Pozo, I. Sánchez-Navarro, A. Pinto, C. A. Castañeda, E. Ciruelos, J. Feliu, J. A.Fresno Vara

Research output: Contribution to journalScientific review

12 Scopus citations

Abstract

Gene signatures can provide prognostic and predictive information to help in the treatment of early-stage breast cancer. Although many of these signatures have been described, only a few have been properly validated. MammaPrint and OncoType offer prognostic information and identify low-risk patients who do not benefit from adjuvant chemotherapy. With regard to prediction of response, molecular subtypes of breast cancer differ in their sensitivity to chemotherapy, although further studies are needed in this field. Cost, small sample size, and the need to use central laboratories are common limitations to the widespread use of these tools.
Original languageAmerican English
Pages (from-to)41-46
Number of pages6
JournalCancer metastasis reviews
DOIs
StatePublished - 1 Jan 2012

Fingerprint Dive into the research topics of 'The present and future of gene profiling in breast cancer.'. Together they form a unique fingerprint.

  • Cite this

    Espinosa, E., Gámez-Pozo, A., Sánchez-Navarro, I., Pinto, A., Castañeda, C. A., Ciruelos, E., Feliu, J., & Vara, J. A. F. (2012). The present and future of gene profiling in breast cancer. Cancer metastasis reviews, 41-46. https://doi.org/10.1007/s10555-011-9327-7